Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Brazil could approve Russian coronavirus vaccine in days, says pharmaceutical firm

Published 03/23/2021, 07:05 PM
Updated 03/23/2021, 07:10 PM
© Reuters. FILE PHOTO: Bottles of Russia's "Sputnik-V" COVID-19 vaccine

BRASILIA (Reuters) - The Brazilian pharmaceutical company that plans to produce Russia's coronavirus vaccine Sputnik V said on Tuesday it expects to overcome regulatory obstacles in "two or three" days to obtain authorization to make and sell the shot in Brazil.

After a 5-hour video conference with União Quimica executives and members of Moscow's Gamaleya Institute, Brazil's health regulator Anvisa said there was still information missing before it could approve the vaccine.

"Anvisa still requires a few more things from Moscow on their Phase 3 trials and I expect to deliver those in two or three days," the company's chief executive and owner Fernando Marques said.

União Quimica requested emergency use authorization more than two months ago and Marques has complained that "political interests" have held up the approval process for vaccine that is being used in Russia and 40 other countries.

Marques said his company still hopes to start producing the vaccine in April at its Brasilia plant, but a shipment offered by Moscow of 10 million ready-made doses in the first quarter to this year has been lost.

With Brazil's dire need of vaccines to quell a surge of COVID-19 that made it the epicenter of the pandemic, another source of shots has been sought by state governments unhappy with the slow vaccination program.

So far, less than 8% of the country's 210 million people have had their first shot, and les than 3% both shots, while deaths from COVID-19 have surged to record levels in the last two weeks driven by a contagious new local variant.

Anvisa said in a statement the meeting dealt with "critical" issues that the developers of Sputnik V have not responded to, included the full results of late stage trials in Russia and access to the data bank of studies on the vaccine.

© Reuters. FILE PHOTO: Bottles of Russia's

Anvisa said it also wanted details for quality control of the vaccine's production in Russia, though it has certified the production line based on a Turkish report for another product.

Latest comments

Russia just doing with number how you can have 8k and 400+ deaths thats almost 5% deaths . I think so they are just showing the world that we are in control but something big is coming
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.